Prospective, double-blind, placebo-controlled trial of low-dose amiodarone in patients with severe heart failure and asymptomatic frequent ventricular ectopy

Sudden cardiac death is a common cause of mortality in patients with congestive heart failure. To determine if low-dose amiodarone could reduce sudden death among these patients, a prospective, placebo-controlled, double-blind pilot trial was conducted. One hundred one patients with ejection fractions <30%, New York Heart Association class III or IV symptoms, and frequent but asymptomatic spontaneous ventricular ectopy (Lown class II to V) were randomly assigned to treatment with low-dose amiodarone (400 mg/day for 4 weeks and then 200 mg/day) or placebo. Mean follow-up was 357 days (range 4 to 1009 days). Side effects were infrequent and there was no difference in the incidence of side effects between the treatment groups. The frequency of spontaneous ventricular ectopy in the group receiving amiodarone fell from 4992 to 1240 beats/24 hours at baseline to 1135 ± 494 beats/24 hours after 1 month of treatment (p = 0.02) and remained low after 6 months, while there was no change in ventricular ectopy among the patients receiving placebo. Despite the reduction in ectopy, there was no improvement in mortality or decrease in the incidence of sudden death. One-year mortality by Kaplan-Meier analysis was 28% in the group receiving amiodarone and 19% in the group receiving placebo (p = NS). One-year mortality in patients with >75% reduction in ventricular ectopy after 1 month of treatment was 31% versus 17% in patients with ≤75% ectopic suppression (p = NS). Although the size of the trial and its statistical power do not eliminate the possibility of a significant reduction in mortality with low-dose amiodarone, any effect is likely to be modest, i.e., <25%. Therefore low-dose amiodarone can be safely administered to patients with severely impaired myocardial function and will significantly suppress spontaneous ventricular ectopy. However, despite arrhythmia suppression, low-dose amiodarone may not reduce or may have only a modest effect on the incidence of sudden death in patients with heart failure and asymptomatic ventricular ectopy. (Am Heart J 1991;122:1016.)

John M. Nicklas, MD, William J. McKenna, MD, Ralph A. Stewart, MD, Judith K. Mickelson, MD, Sunil K. Das, MD, M. Anthony Schork, PhD, Shirley J. Krikler, MD, Laurie A. Quain, RN, Fred Morady, MD, and Bertram Pitt, MD. Ann Arbor, Mich., and London, England

Sudden cardiac death has been reported to account for nearly half of the mortality among patients with congestive heart failure. Although the pathophysiology is unknown, these sudden deaths are thought to be caused by malignant ventricular arrhythmias. In an attempt to prevent sudden death and improve survival, antiarrhythmic therapy is often prescribed prophylactically. However, the effect of antiarrhythmic agents on the incidence of sudden death and overall mortality in patients with heart failure has not been tested in controlled trials. Therefore we conducted a prospective, double-blind pilot trial comparing treatment with the antiarrhythmic drug, amiodarone, versus placebo in patients with congestive heart failure and frequent asymptomatic ventricular ectopy to determine the safety of the treatment regimen, the feasibility of carrying out a large-scale mortality trial with an agent with the potential to cause serious toxicity, and to gain initial insight into the likelihood of reducing the incidence of sudden death with this agent.

From the Divisions of Cardiology, University of Michigan; and the Hammersmith Hospital, London.
Dr. Nicklas was supported by Clinical Investigator Award No. HL01170 from the National Institutes of Health, Bethesda, Md. Dr. McKenna was supported by a grant from the British Heart Foundation.
Received for publication Feb. 5, 1991; accepted April 1, 1991.
Reprint requests: John M. Nicklas, MD, 3010 Taubman, University of Michigan Hospitals, 1500 E. Medical Center Dr., Ann Arbor, MI 48109-0866.
METHODS

Patients. Patients ages 21 years or older with congestive heart failure referred to the University of Michigan Hospital, the Veterans Administration Hospital in Ann Arbor, or the Hammersmith Hospital in London were eligible for study. The entry criteria were: (1) New York Heart Association (NYHA) class III or IV heart failure symptoms; (2) left ventricular ejection fraction ≤30%; and (3) Lown class II to V ventricular ectopy recorded during 24-hour ambulatory electrocardiographic monitoring. Patients were excluded if they had a history of symptoms attributable to ventricular ectopy including lightheadedness, dizziness, syncope, or if they were already receiving antiarrhythmic drugs. Patients with palpitations were not excluded. All patients gave informed written consent as approved by their hospital's Committee for Human Subjects. The study population consisted of 101 patients, 86 men and 15 women, aged 26 to 78 years (mean 57 years).

Study design. Forty-nine patients were randomly chosen to receive amiodarone and 52 to receive placebo. The dose of amiodarone was 400 mg/day orally for 4 weeks, followed by a maintenance oral dose of 200 mg/day. The study medication was administered in a double-blind fashion. Serial chest roentgenograms, electrocardiograms, and serum potassium and magnesium levels were obtained every 3 months. Chest roentgenograms were examined for evidence of interstitial fibrosis. The development of heart block or intraventricular conduction delay was assessed from the electrocardiograms. Abnormalities in serum electrolyte levels were immediately corrected with oral supplementation. To avoid digitalis toxicity, the dose of digoxin was reduced to 0.125 mg/day in patients receiving >0.125 mg/day of digoxin. Patients were specifically queried for symptoms of photosensitivity, tremor, ataxia, nausea, and constipation every 3 months. Follow-up 24-hour ambulatory monitoring was performed after 1 month and after 6 months of study to assess suppression of ventricular ectopics and complex ventricular ectopy including couplets and ventricular tachycardia. Ventricular tachycardia was defined as three or more consecutive ventricular ectopics at a mean rate ≥120 beats/min. Side effect and survival data were reviewed by a safety committee (MAS and BP), blinded by group, at 6-month intervals.

The trial was designed for a mean follow-up of 1 year. Sample size calculations were based on the following assumptions: (1) The 1-year cardiovascular mortality rate in the control population would be 80%. (2) Sudden deaths would account for 50% of total deaths. (3) Amiodarone would reduce the incidence of sudden death at 1 year by 50% and improve survival at 1 year by 25%.

Data analysis. Patient deaths were classified as (1) sudden, if the patient deteriorated and died within 1 hour of the onset of symptoms; (2) progressive, if patient deterioration began ≥1 hour prior to death; (3) infarction-related, if death occurred within 1 week of an acute myocardial infarction; or (4) noncardiac. Patients were withdrawn from the study and were considered to have survived sudden death if they experienced syncope caused by documented ventricular tachycardia or if unexplained syncope occurred.

Table I. Baseline clinical characteristics

<table>
<thead>
<tr>
<th></th>
<th>Amiodarone (n = 49)</th>
<th>Placebo (n = 52)</th>
<th>p</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age (yr)</td>
<td>50 ± 1</td>
<td>59 ± 1</td>
<td>0.18</td>
</tr>
<tr>
<td>Male/Female</td>
<td>41/8</td>
<td>45/7</td>
<td>0.90</td>
</tr>
<tr>
<td>Ischemic/Idiopathic</td>
<td>25/24</td>
<td>28/24</td>
<td>0.93</td>
</tr>
<tr>
<td>Ejection fraction (%)</td>
<td>19 ± 1</td>
<td>21 ± 1</td>
<td>0.18</td>
</tr>
<tr>
<td>NYHA class III/IV</td>
<td>39/10</td>
<td>44/8</td>
<td>0.69</td>
</tr>
<tr>
<td>Duration of symptoms (mo)</td>
<td>32 ± 6</td>
<td>33 ± 5</td>
<td>0.02</td>
</tr>
<tr>
<td>Medications (% of patients)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Digoxin</td>
<td>45</td>
<td>44</td>
<td>0.89</td>
</tr>
<tr>
<td>Loop diuretics</td>
<td>90</td>
<td>90</td>
<td>0.84</td>
</tr>
<tr>
<td>Potassium-sparing diuretics</td>
<td>38</td>
<td>35</td>
<td>0.93</td>
</tr>
<tr>
<td>Angiotensin-converting enzyme inhibitors</td>
<td>61</td>
<td>65</td>
<td>0.92</td>
</tr>
<tr>
<td>Serum electrolytes</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Potassium</td>
<td>4.4 ± 0.1</td>
<td>4.5 ± 0.1</td>
<td>0.47</td>
</tr>
<tr>
<td>Magnesium</td>
<td>2.0 ± 0.1</td>
<td>2.1 ± 0.1</td>
<td>0.71</td>
</tr>
</tbody>
</table>

All data were analyzed according to the intention-to-treat principle. Differences in baseline characteristics between treatment groups were analyzed by the Student's t test or by Fisher's exact test. Kaplan-Meier product limit estimates were used to compare the survival of each treatment group. Savage (Mantel-Cox) statistics were used to assess the significance of associations between baseline characteristics and survival.

RESULTS

Clinical characteristics. There were no significant differences between treatment groups in baseline clinical characteristics (Table I). The average ejection fraction of the study population was <20%. A greater proportion of patients had NYHA class III (n = 83) than NYHA class IV symptoms (n = 18). The average frequency of ventricular ectopy was 4900 ± 830 beats/24 hours. Sixty-two percent of the patients had asymptomatic ventricular tachycardia recorded during baseline monitoring. No patient had an abnormal serum potassium or magnesium level at the time of entry into the study. Symptoms of congestive heart failure had been present for 32 ± 4 months. Medical therapy included digoxin in 45%, loop diuretics (either furosemide or bumetanide) in 90%, potassium-sparing diuretics (either amiloride, triamterene, or spironolactone) in 36%, and angiotensin-converting enzyme inhibitors in 64%. Baseline characteristics were similar between hospitals except that digoxin was more commonly administered to patients treated at the University and Veterans Hospitals than at the Hammersmith Hospital.

Side effects. Patients were followed for between 4 and 1009 days (mean 357 days). No patient developed interstitial fibrosis or a peripheral neuropathy during the trial. Heart block occurred in one patient receiving amiodarone and appeared to initiate sudden...
Fig. 1. Relative frequency and complexity of ventricular ectopy in patients receiving amiodarone (solid bars) or placebo (hatched bars) at baseline and after 1 and 6 months of treatment. There were no statistically significant differences between treatment groups at baseline. After 1 month, total premature ventricular contractions (PVC's), couplets, and ventricular tachycardia were significantly less frequent in the patients receiving amiodarone compared with those receiving placebo, p = 0.02, 0.01, and 0.002, respectively. Similarly, the frequency of ventricular ectopy decreased from baseline in patients receiving amiodarone but remained unchanged in those receiving placebo (*p < 0.05; **p < 0.02).

death. The incidence of other side effects was similar in both groups. A total of 12 patients discontinued their study medication, seven in the amiodarone group and five in the placebo group. Reasons for discontinuation among patients receiving amiodarone included: tremor (n = 2), non-photosensitive rash (n = 1), threefold elevation in hepatic enzymes (n = 1), new onset atrial fibrillation (n = 1), and relocation to another country (n = 2). Reasons for withdrawal among patients receiving placebo included: non-photosensitive rash (n = 1), threfoil elevation in hepatic enzymes (n = 1), new onset atrial fibrillation (n = 1), and cardiac transplantation (n = 2). Two patients, one from each treatment group, were lost to follow-up.

Ventricular ectopic suppression. Significant suppression of ventricular ectopy in patients treated with amiodarone was observed after 1 month and after 6 months of study (Fig. 1). The frequency of ventricular ectopics in the group receiving amiodarone was reduced from 4992 ± 1240 beats/24 hours at baseline to 1135 ± 494 beats/24 hours after 1 month (p = 0.02) and to 1686 ± 770 beats/24 hours after 6 months (p = 0.14). Suppression of more than 75% of all ventricular ectopics was achieved in 60% of the patients receiving amiodarone after 1 month and in 75% after 6 months. In contrast, the frequency of ventricular ectopics did not change significantly in the group receiving placebo, from 4816 ± 1130 beats/24 hours at baseline to 4489 ± 1040 beats/24 hours after 1 month (p = NS) and 4213 ± 1246 beats/24 hours after 6 months (p = NS).

Complex ventricular ectopy was also reduced after 1 month and after 6 months of treatment in the group receiving amiodarone. The frequency of couplets in the group receiving amiodarone was reduced from 145 ± 59 couplets/24 hours at baseline to 32 ± 27 couplets/24 hours after 1 month (p = NS) and to 70 ± 40 couplets/24 hours after 6 months (p = 0.04). The frequency of couplets did not change significantly in the group receiving placebo, from 185 ± 95 couplets/24 hours at baseline to 156 ± 51 couplets/24 hours after 1 month (p = NS) and to 242 ± 114 couplets/24 hours after 6 months (p = NS). The proportion of patients with asymptomatic ventricular tachycardia on 24-hour ambulatory monitoring who received amiodarone was 52% at baseline and 21% (p = 0.01) and 33% (p = NS) after 1 month and after 6 months of study, respectively. Among patients who received placebo, the proportion with asymptomatic ventricular tachycardia was 71% at baseline and 64% (p = NS) and 60% (p = NS) after 1 and after 6 months, respectively.

Study end points. Twenty-six patients died or survived episodes of sudden death during the trial. All deaths were considered to be cardiovascular and no deaths occurred following infarction. Five deaths were classified as progressive pump failures; two of these patients were receiving amiodarone and three were receiving placebo (p = NS). Twenty-one patients died suddenly; 12 of them were receiving amiodarone and nine were receiving placebo (p = NS). Five of the 21 patients who experienced sudden death
survived; two who were receiving amiodarone and three who were receiving placebo (p = NS).

Two patients receiving amiodarone died unexpectedly while undergoing ambulatory monitoring. One of these patients died in his sleep with progressive bradycardia over 30 minutes' duration, ending in asystole. The other patient suffered complete heart block without a ventricular escape rhythm. Neither patient had reported previous lightheadedness or syncope and neither had experienced any symptomatic deterioration in exercise tolerance or resting dyspnea.

Survival. There was no difference in the survival rates between treatment groups (Fig. 2). At 1 year, the overall mortality rate was 24%—28% in the group receiving amiodarone and 19% in the group receiving placebo (p = NS). The absolute and relative differences between groups in 1-year mortality and the statistical power of the trial are illustrated in Fig. 3.

There was also no significant difference in survival between treatment groups in either the ischemic or nonischemic subpopulations (Fig. 4). At 1 year, the mortality rate among patients with ischemic heart disease was 34% for those receiving amiodarone and 19% for those receiving placebo (p = NS). The 1-year mortality among patients with nonischemic cardiomyopathies was 24% versus 27% (p = NS) in those receiving amiodarone and placebo, respectively.

Suppression of spontaneous ventricular ectopy was not associated with an improved prognosis. Patients with greater than 75% suppression of baseline ectopy after 1 month were compared with patients with less suppression (Fig. 5). Four patients died within 1 month of randomization (one receiving amiodarone and three receiving placebo) before undergoing a second 24-hour ambulatory recording to assess the degree of ectopic suppression. At 1 year, the mortality rate among patients with >75% suppression was 23% versus 17% (p = NS) among those with less suppression.

Survival was inversely related to the duration of symptomatic heart failure (p = 0.0065) and New York Heart Association functional class (p = 0.033). Survival was not related to age, sex, ejection fraction, etiology of the cardiomyopathy, serum levels of
patients required pacemaker implantation because they developed adverse effects within 30 months. Six of their patients had to discontinue the medication, 56% depressed ventricular ectopy. However, despite arrhythmia suppression, amiodarone did not reduce the incidence of sudden death or improve survival. The incidence of some side effects may be dose-dependent. For example, Hamer et al.12 reported that low-dose amiodarone (600 mg/day for 2 weeks followed by 200 mg/day maintenance dosage) improved exercise tolerance in 16 patients with severe left ventricular dysfunction and was safe. Nevertheless, nausea was a significant problem in their study and caused 25% of the patients to discontinue amiodarone and placebo. Other investigators have also reported that low-dose amiodarone is well tolerated and is not associated with the development of pulmonary toxicity or peripheral neuropathy.12-14

However, previous reports of the safety of low-dose amiodarone in heart failure patients suggest that the incidence of some side effects may be dose-dependent. For example, Hamer et al.12 reported that low-dose amiodarone (600 mg/day for 2 weeks followed by 200 mg/day maintenance dosage) improved exercise tolerance in 16 patients with severe left ventricular dysfunction and was safe. Nevertheless, nausea was a significant problem in their study and caused 25% of the patients to discontinue amiodarone within 6 months. Most of their patients developed nausea during the 2-week loading phase when they were receiving 600 mg/day of amiodarone. In contrast, nausea may have been avoided in our study by using a lower loading dose of the medication (400 mg/day). Neri et al.13 reported that low-dose amiodarone (600 mg/day for 1 week, 400 mg/day for 1 week, followed by a 200 to 400 mg/day maintenance dose) was safely administered to 41 patients with moderately impaired left ventricular function. Although only four patients had to discontinue the medication, 56% developed adverse effects within 30 months. Six of their patients required pacemaker implantation because of heart block, intraventricular conduction delays, or sick sinus syndrome, and an additional five patients developed sinus bradycardia (<50 beats/min). The absence of these side effects in our study may be attributable to our lower maintenance dose of amiodarone.

Suppression of ventricular ectopy. Although low doses of amiodarone may be safe, they may also be ineffective. However, our study demonstrated that a low dose of amiodarone can significantly suppress both the frequency and complexity of ventricular ectopy in patients with severe heart failure. Total ventricular ectopy was reduced by 75% in the majority of our patients within 1 month of initiating therapy and in 75% within 6 months. The incidence of asymptomatic ventricular tachycardia was reduced by 60% after 1 month and remained low during follow-up. Other investigators have also shown that low-dose amiodarone is effective in reducing ventricular ectopy in heart failure patients. Hauser et al.12 reported that ventricular tachycardia was eliminated in 9 of 14 patients after 6 weeks of treatment with low-dose amiodarone. Neri et al.13 found that the frequency of ventricular ectopy was suppressed by at least 80% in 30 of 41 patients after 3 weeks of treatment. Cleland et al.14 reported that exercise-induced ventricular tachycardia was suppressed in five of five patients receiving low-dose amiodarone.

Survival. Despite low-dose amiodarone’s safety and efficacy in suppressing ventricular ectopy in patients with severe heart failure, we could not detect any reduction in sudden death or prolongation of survival. Although the difference was not statistically significant, overall mortality after 1 year was paradoxically higher in the amiodarone group than in the control group—28% versus 19%. Similarly, there was no reduction in sudden death among the amiodarone-treated patients compared with the controls. The absence of an effect of amiodarone on survival cannot be attributed to a baseline bias. Randomization of the study population divided the patients into two treatment groups with equivalent characteristics (Table I). The baseline variables that were correlated with mortality—the duration of heart failure symptoms and functional class—did not demonstrate a trend favoring survival in the placebo group.

However, the absence of a beneficial effect of low-dose amiodarone on survival in our study can be attributed to the statistical power of the trial. The sample size calculation had assumed a much higher control mortality than what was observed. Given this low control mortality, reductions in mortality up to 25% could not have been reliably detected. There are also other explanations for the absence of an improvement in survival with low-dose amiodarone. Although our dose of amiodarone effectively suppressed ventricular ectopy, the degree of suppression was only partial and higher doses of the drug might have been more effective in not only suppressing ectopy but also in preventing sudden death. However, since higher doses of amiodarone appear to be associated with increased toxicity, any reductions in sudden deaths might be offset by increases in other causes of mortality.
Discrepancy between suppression of ventricular ectopy and prevention of sudden death. The discrepancy between the marked reduction in ventricular ectopy among the amiodarone-treated patients in our study and the absence of any effect on survival is of interest. Both the frequency and complexity of spontaneous ventricular ectopy have been used as indices of the risk of sudden death. This study demonstrates that reductions in asymptomatic ventricular ectopy and the risk of sudden death are not linearly related. A 75% reduction in ectopy was not associated with a 75% reduction in the incidence of sudden death. In fact, patients with >75% reductions in ventricular ectopy had poorer survival than patients with less suppression (Fig. 4). Investigators in the Cardiac Arrhythmia Suppression Trial (CAST) found a similar discrepancy between arrhythmia suppression and survival in patients with asymptomatic ventricular ectopy following a myocardial infarction. In their study, patients treated with encainide or flecainide had a three- to fourfold higher incidence of sudden death than patients who received placebo despite effective suppression of ventricular ectopy by both antiarrhythmic agents. Our trial and the CAST study emphasize the need to document the efficacy of antiarrhythmic agents. The excellent graphics support of Susan J. Schreiber is gratefully acknowledged.

REFERENCES